Associate Professor Nicholas Wilcken

Associate Professor
NHMRC Clinical Trials Centre, Central Clinical School

Telephone 9845 5200
Fax 9845 6391

Map

Biographical details

Medical studies at UNSW, general medical training at Prince of Wales Hospital, oncology training at Royal Prince Alfred, PhD at the Garvan Institute.

Currently Director of Medical Oncology, Westmead Hospital, Senior Staff Specialist at Nepean Hospital, SAC Chair ANZ Breast Cancer Trials Group and Co-ordinating Editor of the Cochrane Collaboration Breast Cancer Group. Chair of SAC for the ANZ Breast Cancer Trials Group.

Research interests

Breast cancer treatment, clinical trials, systematic review, evidence based clinical practice guidelines.

Selected grants

2014

  • Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to down-stage large oestrogen receptor positive breast cancer; Francis P, Wilcken N, Murray N, Forbes J, Redfern A, Boyle F, Spillane A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Cochrane Breast Cancer Group infrastructure funding for support and development of reliable and relevant systematic ‘Cochrane’ reviews in breast cancer; Wilcken N, Goodwin A; National Breast Cancer Foundation/Research Services.

2013

  • Cochrane Breast Cancer group; Wilcken N; National Health and Medical Research Council (NHMRC)/Cochrane Collaboration Funding.

2012

  • A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study); Gurney H, Balleine R, Wilcken N, Liddle C; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • A novel approach to optimizing PARP inhibitor therapy in patients with triple negative and BRCA-associated breast cancer; Friedlander M, Wilcken N, Mitchell G; National Breast Cancer Foundation/Novel Concept Awards.

2009

  • Cochrane Breast Cancer Group; Wilcken N; DHA/Cochrane Collaborative Groups Funding Scheme.

2008

  • The Cochrane Breast Cancer Group; Wilcken N; DHA/Cochrane Collaborative Groups Funding Scheme.

2005

  • Systematic review of interventions for the management of locally advanced breast cancer; Wilcken N, Ghersi D; Cure Cancer Australia Foundation/Research Support.
  • Funding for Australian based cochrane collaberation activities: the cochrane breast cancer group; Wilcken N; DHA/Cochrane Collaborative Groups Funding Scheme.

2001

  • Antidepressants and subjective well-being in advanced cancer: a double-blind randomised trial of Sertraline and St Johns Wort; Stockler M, Wilcken N, Simes R; Cancer Council New South Wales/Research Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 154-161). Sydney: AMPCo.

Journals

  • McCarthy, N., Boyle, F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P., Chirgwin, J., Abdi, E., Gebski, V., Wilcken, N., et al (2014). Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). The Breast, 23(2), 142-151. [More Information]
  • Yee, J., Davis, G., Beith, J., Wilcken, N., Currow, D., Emery, J., Phillips, J., Martin, A., Hui, R., Harrison, M., Kilbreath, S., et al (2014). Physical activity and fitness in women with metastatic breast cancer. Journal of Cancer Survivorship. [More Information]
  • de Boer, R., Beith, J., Chirgwin, J., Chua, S., Colosimo, M., Francis, P., Green, M., Pittman, K., White, M., Wilcken, N., et al (2014). Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives. Asia-Pacific Journal of Clinical Oncology, 10(Suppl S4), 15-25. [More Information]
  • Wilcken, N., Zdenkowski, N., White, M., Snyder, R., Pittman, K., Mainwaring, P., Green, M., Francis, P., de Boer, R., Colosimo, M., et al (2014). Systemic treatment of HER2-positive metastatic breast cancer: A systematic review. Asia-Pacific Journal of Clinical Oncology, 10(S4), 1-14. [More Information]
  • Cass-Verco, J., Mason, C., Wilcken, N. (2013). Antidepressants and tamoxifen: interaction concerns. Australasian Psychiatry, 21(5), 508-509. [More Information]
  • Dear, R., McGeechan, K., Jenkins, M., Barratt, A., Tattersall, M., Wilcken, N. (2013). Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, 2013 (12), 1-91. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Goldhirsch, A., Winer, E., Coates, A., Gelber, R., Piccart-Gebhart, M., Thurlimann, B., Senn, H., Albain, K., Andre, F., Bergh, J., Wilcken, N., et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24(9), 2206-2223. [More Information]
  • Goodwin, A., Parker, S., Ghersi, N., Wilcken, N. (2013). Post-operative radiotherapy for ductal carcinoma in situ of the breast (Review). Cochrane Database of Systematic Reviews, 11, 1-39. [More Information]
  • Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]
  • Goldstein, D., Bennett, B., Webber, K., Boyle, F., De Souza, P., Wilcken, N., Scott, E., Toppler, R., Murie, P., O'Malley, L., Hickie, I., et al (2012). Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. Journal of Clinical Oncology, 30(15), 1805-1812. [More Information]
  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., WONG, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012). Decision making in older patients with advanced cancer: Does doctor know best? Medical Journal of Australia, 196(1), 35-39. [More Information]
  • Wilcken, N. (2012). First story - MJA Dr Eric Dark Creative Writing Prize. Medical Journal of Australia, 197(9), 526-526. [More Information]
  • Balleine, R., Wilcken, N. (2012). High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy. Molecular Diagnosis and Therapy, 16(4), 235-240. [More Information]
  • Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012). Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia, 196(11), 688-692. [More Information]
  • Wilcken, N., Stockler, M. (2012). Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 156(12), 432-444.
  • Cameron, B., Bennett, B., Li, H., Boyle, F., deSouza, P., Wilcken, N., Friedlander, M., Goldstein, D., Lloyd, A. (2012). Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology, 23(11), 2890-2895. [More Information]
  • McCarthy, N., Mitchell, G., Bilous, M., Wilcken, N., Lindeman, G. (2012). Triple-negative breast cancer: making the most of a misnomer. Asia-Pacific Journal of Clinical Oncology, 8(2), 145-155. [More Information]
  • Stockler, M., Wilcken, N. (2012). Why Is Management of Cancer Pain Still a Problem? Journal of Clinical Oncology, 30(16), 1907-1908. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., Bruzzi, P. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 29(16), 2144-2149. [More Information]
  • Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
  • Wilcken, N. (2011). Nine Letters. Lancet Oncology, 12(13), 1193-1194. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Tattersall, M., et al (2011). Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 29(15), 2077-2084. [More Information]
  • de Boer, R., Chan, A., Tran, B., Wilcken, N. (2011). Use of non-anthracycline regimens in early stage breast cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 7(1), 4-10. [More Information]
  • Butters, D., Ghersi, D., Wilcken, N., Kirk, S., Mallon, P. (2010). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews, 11(1), CD003368. [More Information]
  • Barratt, A., Tattersall, M., McGeechan, K., Dear, R., Wilcken, N. (2010). Combination versus sequential single agent chemotherapy for metastatic breast cancer (Protocol). Cochrane Database of Systematic Reviews, 2010 (10), 1-8. [More Information]
  • Dickersin, K., Tovey, D., Wilcken, N., Ghersi, D. (2010). The background review for the USPSTF recommendation on screening for breast cancer. Annals of Internal Medicine, 152(8), 537; author reply 538-9. [More Information]
  • Snyder, R., Boyle, F., Chan, A., Craft, P., de Boer, R., Mainwaring, P., McCarthy, N., Wilcken, N. (2009). Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. Asia-Pacific Journal of Clinical Oncology, 5(1), 4-16.
  • Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009). Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000563.pub6.(3), 1-35. [More Information]
  • Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009). Post-operative radiotherapy for ductal carcinoma in situ of the breast - a systematic review of the randomised trials. The Breast, 18(3), 143-149. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, (2), CD003372-1-CD003372-109. [More Information]
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N. (2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 20(11), 1771-1785. [More Information]
  • Dear, R., Wilcken, N., Shannon, J. (2008). Beyond chemotherapy: Demystifying the new 'targeted' cancer treatments. Australian Family Physician, 37(1-2), 45-49. [More Information]
  • Wilcken, N., Dear, R. (2008). Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. European Journal of Cancer, 44(15), 2218-2225. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]
  • Smith, I., Procter, M., Gelber, R., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., Wilcken, N., et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet, 369(9555), 29. [More Information]
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, 8(7), 603-612. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology and Therapeutics, 82(1), 33-40. [More Information]
  • Wilcken, N., Stockler, M. (2007). Ovarian suppression for early breast cancer. The Lancet, 369, 1668-1670. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59.
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N., et al (2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 18(2), 215-225. [More Information]
  • Ahern, V., Boyages, J., Gebski, V., Moon, D., Wilcken, N. (2007). Selective Mastectomy in the Management of Locally Advanced Breast Cancer. International Journal of Radiation: Oncology - Biology - Physics, 68. [More Information]
  • Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., Nowak, A. (2007). Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews, Art. No.: CD004421(4), 1-50. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Tattersall, M., Goldstein, D. (2007). When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer. Journal of Clinical Oncology, 25(18S), 6509.
  • Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.
  • Boyages, J., Taylor, R., Chua, B., Ung, O., Bilous, M., Salisbury, E., Wilcken, N. (2006). A risk index for early node-negative breast cancer. British Journal of Surgery, 93(5), 564-571. [More Information]
  • Jones, D., Ghersi, D., Wilcken, N. (2006). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews, 19(3), CD003368-CD003368. [More Information]
  • Stevanovic, A., Lee, P., Wilcken, N. (2006). Metastatic breast cancer. Australian Family Physician, 35(5), 309-12. [More Information]
  • Ghersi, D., Wilcken, N., Simes, R. (2005). A systematic review of taxane-containing regimens for metastatic breast cancer. British Journal of Cancer, 93(3), 293-301. [More Information]
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
  • Coombs, N., Taylor, R., Wilcken, N., Fiorica, J., Boyages, J. (2005). Hormone Replacement Therapy and Breast Cancer Risk in California. The Breast Journal, 11(6), 410-415. [More Information]
  • Coombs, N., Taylor, R., Wilcken, N., Boyages, J. (2005). Hormone replacement therapy and breast cancer: estimate of risk. BMJ: British Medical Journal, 331(7512), 347-349. [More Information]
  • Coombs, N., Taylor, R., Wilcken, N., Boyages, J. (2005). HRT and breast cancer: Impact on population risk and incidence. European Journal of Cancer, 41(12), 1775-1781. [More Information]
  • Brennan, M., Wilcken, N., French, J., Ung, O., Boyages, J. (2005). Management of early breast cancer - the current approach. Australian Family Physician, 34(9), 755-760.
  • Brennan, M., Wilcken, N., Ung, O., Boyages, J. (2005). Management of early breast cancer--the current approach. Australian Family Physician, 34(9), 755-60. [More Information]
  • Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2005). Single agent versus combination chemotherapy for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-22. [More Information]
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2005). Taxane containing regimens for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-119. [More Information]
  • Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncology, 6(8), 581-588. [More Information]
  • Lord, S., Ghersi, D., Gattellari, M., Wilcken, N., Thornton, C., Simes, J. (2004). Antitumour Antibiotic Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 4(CD003367), 1-123.
  • Carrick, S., Ghersi, D., Wilcken, N., Simes, R. (2004). Platinum Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 2(CD003374), 1-74.
  • Nowak, A., Wilcken, N., Stockler, M., Hamilton, A., Ghersi, D. (2004). Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer. Lancet Oncology, 5(6), 372-380.
  • Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? Breast Cancer Research and Treatment, 81(Suppl 1), S49-S52.
  • Beslija, S., Bonneterre, J., Burstein, H., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Stockler, M., et al (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 81(Supplement 1), S1-S7.
  • Wilcken, N., Stockler, M. (2003). Fulvestrant: spreading the word, but not too thinly. The Lancet, 11, 1254-1254.
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2003). Taxane containing regimes for metastatic breast cancer. Cochrane Database of Systematic Reviews, 168(37), 3117-3120. [More Information]
  • Boyages, J., Chua, B., Taylor, R., Bilous, M., Salisbury, E., Wilcken, N., Ung, O. (2002). Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. British Journal of Surgery, 89(6), 789-796.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168.

2014

  • McCarthy, N., Boyle, F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P., Chirgwin, J., Abdi, E., Gebski, V., Wilcken, N., et al (2014). Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). The Breast, 23(2), 142-151. [More Information]
  • Yee, J., Davis, G., Beith, J., Wilcken, N., Currow, D., Emery, J., Phillips, J., Martin, A., Hui, R., Harrison, M., Kilbreath, S., et al (2014). Physical activity and fitness in women with metastatic breast cancer. Journal of Cancer Survivorship. [More Information]
  • de Boer, R., Beith, J., Chirgwin, J., Chua, S., Colosimo, M., Francis, P., Green, M., Pittman, K., White, M., Wilcken, N., et al (2014). Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives. Asia-Pacific Journal of Clinical Oncology, 10(Suppl S4), 15-25. [More Information]
  • Wilcken, N., Zdenkowski, N., White, M., Snyder, R., Pittman, K., Mainwaring, P., Green, M., Francis, P., de Boer, R., Colosimo, M., et al (2014). Systemic treatment of HER2-positive metastatic breast cancer: A systematic review. Asia-Pacific Journal of Clinical Oncology, 10(S4), 1-14. [More Information]

2013

  • Cass-Verco, J., Mason, C., Wilcken, N. (2013). Antidepressants and tamoxifen: interaction concerns. Australasian Psychiatry, 21(5), 508-509. [More Information]
  • Dear, R., McGeechan, K., Jenkins, M., Barratt, A., Tattersall, M., Wilcken, N. (2013). Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, 2013 (12), 1-91. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Goldhirsch, A., Winer, E., Coates, A., Gelber, R., Piccart-Gebhart, M., Thurlimann, B., Senn, H., Albain, K., Andre, F., Bergh, J., Wilcken, N., et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24(9), 2206-2223. [More Information]
  • Goodwin, A., Parker, S., Ghersi, N., Wilcken, N. (2013). Post-operative radiotherapy for ductal carcinoma in situ of the breast (Review). Cochrane Database of Systematic Reviews, 11, 1-39. [More Information]
  • Kiely, B., Martin, A., Tattersall, M., Nowak, A., Goldstein, D., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Stockler, M., et al (2013). The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. Journal of Clinical Oncology, 31(28), 3565-3571. [More Information]

2012

  • Goldstein, D., Bennett, B., Webber, K., Boyle, F., De Souza, P., Wilcken, N., Scott, E., Toppler, R., Murie, P., O'Malley, L., Hickie, I., et al (2012). Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. Journal of Clinical Oncology, 30(15), 1805-1812. [More Information]
  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., WONG, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012). Decision making in older patients with advanced cancer: Does doctor know best? Medical Journal of Australia, 196(1), 35-39. [More Information]
  • Wilcken, N. (2012). First story - MJA Dr Eric Dark Creative Writing Prize. Medical Journal of Australia, 197(9), 526-526. [More Information]
  • Balleine, R., Wilcken, N. (2012). High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy. Molecular Diagnosis and Therapy, 16(4), 235-240. [More Information]
  • Lord, S., Marinovich, M., Patterson, J., Wilcken, N., Kiely, B., Gebski, V., Crossing, S., Roder, D., Gattellari, M., Houssami, N. (2012). Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis. Medical Journal of Australia, 196(11), 688-692. [More Information]
  • Wilcken, N., Stockler, M. (2012). Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 156(12), 432-444.
  • Cameron, B., Bennett, B., Li, H., Boyle, F., deSouza, P., Wilcken, N., Friedlander, M., Goldstein, D., Lloyd, A. (2012). Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology, 23(11), 2890-2895. [More Information]
  • McCarthy, N., Mitchell, G., Bilous, M., Wilcken, N., Lindeman, G. (2012). Triple-negative breast cancer: making the most of a misnomer. Asia-Pacific Journal of Clinical Oncology, 8(2), 145-155. [More Information]
  • Stockler, M., Wilcken, N. (2012). Why Is Management of Cancer Pain Still a Problem? Journal of Clinical Oncology, 30(16), 1907-1908. [More Information]

2011

  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., Bruzzi, P. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 29(16), 2144-2149. [More Information]
  • Kiely, B., Wilcken, N., Stockler, M. (2011). Life after adjuvant chemotherapy for breast cancer: the news is mostly good. Journal of Clinical Oncology, 29(9), 1092-1093. [More Information]
  • Wilcken, N. (2011). Nine Letters. Lancet Oncology, 12(13), 1193-1194. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Tattersall, M., et al (2011). Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of Clinical Oncology, 29(15), 2077-2084. [More Information]
  • de Boer, R., Chan, A., Tran, B., Wilcken, N. (2011). Use of non-anthracycline regimens in early stage breast cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 7(1), 4-10. [More Information]

2010

  • Butters, D., Ghersi, D., Wilcken, N., Kirk, S., Mallon, P. (2010). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews, 11(1), CD003368. [More Information]
  • Barratt, A., Tattersall, M., McGeechan, K., Dear, R., Wilcken, N. (2010). Combination versus sequential single agent chemotherapy for metastatic breast cancer (Protocol). Cochrane Database of Systematic Reviews, 2010 (10), 1-8. [More Information]
  • Dickersin, K., Tovey, D., Wilcken, N., Ghersi, D. (2010). The background review for the USPSTF recommendation on screening for breast cancer. Annals of Internal Medicine, 152(8), 537; author reply 538-9. [More Information]

2009

  • Snyder, R., Boyle, F., Chan, A., Craft, P., de Boer, R., Mainwaring, P., McCarthy, N., Wilcken, N. (2009). Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. Asia-Pacific Journal of Clinical Oncology, 5(1), 4-16.
  • Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009). Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000563.pub6.(3), 1-35. [More Information]
  • Goodwin, A., Parker, S., Ghersi, D., Wilcken, N. (2009). Post-operative radiotherapy for ductal carcinoma in situ of the breast - a systematic review of the randomised trials. The Breast, 18(3), 143-149. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, (2), CD003372-1-CD003372-109. [More Information]
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N. (2009). Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 20(11), 1771-1785. [More Information]

2008

  • Dear, R., Wilcken, N., Shannon, J. (2008). Beyond chemotherapy: Demystifying the new 'targeted' cancer treatments. Australian Family Physician, 37(1-2), 45-49. [More Information]
  • Wilcken, N., Dear, R. (2008). Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. European Journal of Cancer, 44(15), 2218-2225. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]

2007

  • Smith, I., Procter, M., Gelber, R., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., Wilcken, N., et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet, 369(9555), 29. [More Information]
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, 8(7), 603-612. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology and Therapeutics, 82(1), 33-40. [More Information]
  • Wilcken, N., Stockler, M. (2007). Ovarian suppression for early breast cancer. The Lancet, 369, 1668-1670. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Boyle, F., Beith, J., Wilcken, N., Heritier, S., Coates, A., Simes, R., Stockler, M. (2007). Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 16(1), 48-59.
  • Wilcken, N., Gebski, V., Pike, R., Keech, A. (2007). Putting results of a clinical trial into perspective. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 154-161). Sydney: AMPCo.
  • Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Kostler, W., Krainer, M., Stockler, M., Wilcken, N., et al (2007). Second consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 18(2), 215-225. [More Information]
  • Ahern, V., Boyages, J., Gebski, V., Moon, D., Wilcken, N. (2007). Selective Mastectomy in the Management of Locally Advanced Breast Cancer. International Journal of Radiation: Oncology - Biology - Physics, 68. [More Information]
  • Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., Nowak, A. (2007). Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews, Art. No.: CD004421(4), 1-50. [More Information]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Tattersall, M., Goldstein, D. (2007). When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer. Journal of Clinical Oncology, 25(18S), 6509.
  • Wilcken, N., Gebski, V., Keech, A., Pike, R. (2007). Words, Words, Words. Medical Journal of Australia, 187(4), 256-256.

2006

  • Boyages, J., Taylor, R., Chua, B., Ung, O., Bilous, M., Salisbury, E., Wilcken, N. (2006). A risk index for early node-negative breast cancer. British Journal of Surgery, 93(5), 564-571. [More Information]
  • Jones, D., Ghersi, D., Wilcken, N. (2006). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database of Systematic Reviews, 19(3), CD003368-CD003368. [More Information]
  • Stevanovic, A., Lee, P., Wilcken, N. (2006). Metastatic breast cancer. Australian Family Physician, 35(5), 309-12. [More Information]

2005

  • Ghersi, D., Wilcken, N., Simes, R. (2005). A systematic review of taxane-containing regimens for metastatic breast cancer. British Journal of Cancer, 93(3), 293-301. [More Information]
  • Duric, V., Stockler, M., Butow, P., Sharpe, L., Heritier, S., Beith, J., Boyle, F., Wilcken, N., Coates, A., Simes, R. (2005). Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology, 23(16S), 546S-546S.
  • Coombs, N., Taylor, R., Wilcken, N., Fiorica, J., Boyages, J. (2005). Hormone Replacement Therapy and Breast Cancer Risk in California. The Breast Journal, 11(6), 410-415. [More Information]
  • Coombs, N., Taylor, R., Wilcken, N., Boyages, J. (2005). Hormone replacement therapy and breast cancer: estimate of risk. BMJ: British Medical Journal, 331(7512), 347-349. [More Information]
  • Coombs, N., Taylor, R., Wilcken, N., Boyages, J. (2005). HRT and breast cancer: Impact on population risk and incidence. European Journal of Cancer, 41(12), 1775-1781. [More Information]
  • Brennan, M., Wilcken, N., French, J., Ung, O., Boyages, J. (2005). Management of early breast cancer - the current approach. Australian Family Physician, 34(9), 755-760.
  • Brennan, M., Wilcken, N., Ung, O., Boyages, J. (2005). Management of early breast cancer--the current approach. Australian Family Physician, 34(9), 755-60. [More Information]
  • Duric, V., Stockler, M., Heritier, S., Boyle, F., Beith, J., Sullivan, A., Wilcken, N., Coates, A., Simes, R. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Annals of Oncology, 16(11), 1786-1794. [More Information]
  • Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, R., Wilcken, N. (2005). Single agent versus combination chemotherapy for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-22. [More Information]
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2005). Taxane containing regimens for metastatic breast cancer (Review). Cochrane Database of Systematic Reviews, 2005 (2), 1-119. [More Information]
  • Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncology, 6(8), 581-588. [More Information]

2004

  • Lord, S., Ghersi, D., Gattellari, M., Wilcken, N., Thornton, C., Simes, J. (2004). Antitumour Antibiotic Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 4(CD003367), 1-123.
  • Carrick, S., Ghersi, D., Wilcken, N., Simes, R. (2004). Platinum Containing Regimens For Metastatic Breast Cancer. Cochrane Database of Systematic Reviews, 2(CD003374), 1-74.
  • Nowak, A., Wilcken, N., Stockler, M., Hamilton, A., Ghersi, D. (2004). Systematic Review Of Taxane-Containing Versus Non-Taxane-Containing Regimens For Adjuvant And Neoadjuvant Treatment Of Early Breast Cancer. Lancet Oncology, 5(6), 372-380.

2003

  • Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? Breast Cancer Research and Treatment, 81(Suppl 1), S49-S52.
  • Beslija, S., Bonneterre, J., Burstein, H., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Stockler, M., et al (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 81(Supplement 1), S1-S7.
  • Wilcken, N., Stockler, M. (2003). Fulvestrant: spreading the word, but not too thinly. The Lancet, 11, 1254-1254.
  • Ghersi, D., Wilcken, N., Simes, R., Donoghue, E. (2003). Taxane containing regimes for metastatic breast cancer. Cochrane Database of Systematic Reviews, 168(37), 3117-3120. [More Information]

2002

  • Boyages, J., Chua, B., Taylor, R., Bilous, M., Salisbury, E., Wilcken, N., Ung, O. (2002). Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. British Journal of Surgery, 89(6), 789-796.

2001

  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Larger vs smaller dose of the same drug/s regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Platinum containing reimens for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Single agent vs combination chemotherapy for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Taxane containing regimens for metastatsic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Two drug combinations vs combinations of 3 or more cytotoxic drugs for meastatic brest cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.

2000

  • Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168.

To update your profile click here. For support on your academic profile contact .